Timothy Coughlin - 31 Oct 2025 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Reporting relationship: Director
Issuer ticker: TVTX
Reported as of: 31 Oct 2025
Net transaction value: -$325,561
SEC form: 4
Accepted by SEC: 04 Nov 2025, 16:05:13 UTC
Prior SEC filing: 05 Jun 2025
Next SEC filing: 13 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Elizabeth E. Reed, Attorney-in-Fact

Key filing fact

Timothy Coughlin filed Form 4 for Travere Therapeutics, Inc. (TVTX) on 04 Nov 2025.

Key facts

This page summarizes Timothy Coughlin's Form 4 filing for Travere Therapeutics, Inc. (TVTX).
5 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Nov 2025, 16:05.

Change

Previous filing in this sequence was filed on 05 Jun 2025.
Current net transaction value: -$325,561.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001376043 Primary reporting owner

Coughlin Timothy

Relationship: Director
Address: C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DR., SUITE 300, SAN DIEGO
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Signature date: 03 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TVTX transaction

Common Stock

Options Exercise

Transaction value: $130,640
Shares: +8,000
Change %: +14%
Price: $16.33
Shares after: 63,500
Date: 31 Oct 2025
Ownership: Direct

TVTX transaction

Common Stock

Options Exercise

Transaction value: $174,400
Shares: +10,000
Change %: +16%
Price: $17.44
Shares after: 73,500
Date: 31 Oct 2025
Ownership: Direct

TVTX transaction

Common Stock

Sale

Transaction value: $630,601
Shares: -18,000
Change %: -24%
Price: $35.03
Shares after: 55,500
Date: 31 Oct 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TVTX transaction Derivative

Director stock option (right to buy)

Options Exercise

Transaction value: $0
Shares: -8,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 31 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 8,000
Exercise price: $16.33
Footnotes: F3

TVTX transaction Derivative

Director stock option (right to buy)

Options Exercise

Transaction value: $0
Shares: -10,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 31 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $17.44
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

Footnote F2

The weighted average sale price for the transaction reported was $35.0334, and the range of prices were between $35.00 and $35.15. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

Footnote F3

The stock option is fully vested and exercisable.